Switch to:
More From Other Websites
FDA approves Horsham biotech firm’s drug for Crohn’s disease Sep 28 2016
7 Giant Companies Raising Their Dividends for 25 Years or More Sep 28 2016
Blockbuster biotech deal coming? Sep 27 2016
Perry Capital’s Long-Term Holdings as It Plans to “Wind Down” Sep 27 2016
Amgen: The Blame Game Sep 27 2016
What Analysts Are Recommending for Johnson & Johnson Now Sep 27 2016
Wall Street Sells Off on Worries Over Clinton-Trump Showdown Sep 26 2016
Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies Sep 26 2016
Research finds talc doesn't cause cancer; juries disagree Sep 26 2016
Research finds talc doesn't cause cancer; juries disagree Sep 26 2016
J&J Finally Returning to Its Roots in Diversity? Sep 26 2016
vTv Therapeutics Shares Initiated With Buy Rating, $13 Target Sep 26 2016
A Look at Johnson & Johnson’s Recent Stock Performance Sep 26 2016
New Crohn’s Disease Drug Approved by FDA Sep 26 2016
FDA approves J&J's autoimmune drug Stelara for Crohn's disease Sep 26 2016
Inside Johnson & Johnson’s Latest US Medical Device Launch Sep 26 2016


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK